Literature DB >> 7483773

MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland.

H Johnson1, I B Hillary, G McQuoid, B A Gilmer.   

Abstract

OBJECTIVE: Following the introduction of a national measles and subsequent MMR vaccination programme, to determine the susceptibility of 3-14-year-old children to measles, mumps and rubella and to relate the results to the epidemiology of measles and the need for vaccination policy changes.
DESIGN: Cross-sectional sero-survey and trends in measles notifications and mortality.
SETTING: Paediatric hospital outpatient departments in Dublin.
SUBJECTS: Sera were collected from 837 children attending the clinics in 1991 and 1992.
RESULTS: The prevalence of antibodies in children aged 3-6, 7-10 and 11-14 years was 84, 83 and 95% for measles; 48, 60 and 65% for mumps; and 78, 63 and 74% for rubella, respectively. The prevalence of mumps antibodies may be underestimated. Ninety-six per cent of girls aged 13-14 years had rubella antibodies. A widespread outbreak of measles occurred in 1993. Over recent years, an increasing proportion of measles notifications were in older children.
CONCLUSION: Given sub-optimal uptake of MMR vaccine, outbreaks of infection in pre- and primary school children are inevitable. In such circumstances, a 2-shot MMR vaccine programme with high uptake is essential to prevent a shift of disease into older age groups.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7483773     DOI: 10.1016/0264-410x(94)00021-e

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  1 in total

1.  Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine.

Authors:  Marcelo H Argüelles; Mariana L Orellana; Alejandro A Castello; Guillermo A Villegas; Matilde Masini; Alejandra L Belizan; Silvia González Ayala; Osmar D Vera; Graciela Glikmann
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.